Table 1 Baseline characteristics of trial patients
AutoKinetics (132) | Control (120) | |
|---|---|---|
Age, mean (IQR)—years | 68 (60–75) | 67 (56–74) |
Male, n (%) | 90 (68.2) | 82 (68.3) |
Body Mass Index, median (IQR)—kg/m2 | 25.5 (23.4–29.7) | 26.0 (22.5–29.3) |
Weight, median (IQR)—kg | 80 (70–91) | 80 (70–92) |
SOFA score on day of randomisation, median (IQR) | 10.0 (7.0–13.0) | 10.0 (7.0–12.0) |
Leukocytes at randomisation (*10^9), median (IQR) | 14.7 (8.9–22.1) | 13.3 (8.4–18.7) |
C-reactive protein at randomisation, median (IQR) | 142.0 (71.0–296.2) | 165.0 (65.0–283.0) |
Creatinine at randomisation, median (IQR) | 117.5 (78.2–165.5) | 126.0 (77.0–197.5) |
Septic shocka at randomisation, n (%) | 48 (36.4) | 63 (52.5) |
KDIGO stage at randomisation, n (%) | ||
0 | 80 (60.6) | 68 (56.7) |
1 | 32 (24.2) | 28 (23.3) |
2 | 9 (6.8) | 15 (12.5) |
3 | 11 (8.3) | 9 (7.5) |
Comorbidities, n (%) | ||
Diabetes | 18 (21.4) | 11 (14.3) |
Renal insufficiency | 16 (12.1) | 15 (12.5) |
Cardiovascular insufficiency | 9 (6.8) | 6 (5.0) |
Malignancy | 24 (18.2) | 22 (18.4) |
Immunological insufficiency | 29 (22.0) | 27 (22.5) |
Primary affected organ system upon admission, n (%) | ||
Cardiovascular | 71 (54.2) | 99 (55.0) |
Respiratory | 31 (23.7) | 32 (26.7) |
Gastrointestinal | 18 (13.7) | 16 (14.4) |
Trauma | 5 (3.8) | 3 (2.5) |
Neurologic | 3 (2.3) | 1 (0.8) |
Other | 5 (3.8) | 2 (1.6) |
Admission characteristics | ||
Time from ICU admission until randomisation, median (IQR)—hours | 3.4 (0.9–23.6) | 5.5 (0.8–21.1) |
Antibiotic course initiation after randomisation, n (%) | 74 (56.9) | 76 (63.9) |
Primary antibiotic, n (%) | ||
Vancomycin | 16 (12.1) | 16 (13.3) |
Ciprofloxacin | 49 (37.1) | 43 (35.8) |
Meropenem | 24 (18.2) | 20 (16.7) |
Ceftriaxone | 43 (32.6) | 41 (34.2) |
Coadministered study antibiotic, n (%) | ||
Vancomycin | 29 (22.0) | 26 (21.7) |
Ciprofloxacin | 33 (25.0) | 38 (31.7) |
Meropenem | 13 (9.8) | 5 (4.2) |
Ceftriaxone | 31 (23.5) | 28 (23.3) |